2200 Sand Hill Road
15 articles with 5AM Ventures
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.
A large part of the funding will go to the research and development of CIN-107 as it has shown the potential to treat primary aldosteronism and treatment-resistant hypertension.
Ensoma Taps Gene Therapy Leader as First CEO
10/11/2021After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO.
Expansion said much of the funds will go into its SMiRNA platform to find clinical candidates in myotonic DM1, FTD, ALS, and several other tauopathies.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups
Research platform enables biotech startups to outsource everything but the genius
In October, 5AM Ventures announced plans to raise $350 million for its sixth fund and it seems that the company has hit its mark. The money in that fund will be used to support the formation and development of new biotech companies.
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.
Cabaletta Bio launched out of the University of Pennsylvania with an exclusive license deal and two multi-year sponsored research agreements. The fledgling biotech company will work on engineered T cell products for B cell-mediated autoimmune disease.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).
Bay Area VC Firm 5AM Ventures Rakes in $285 Million Life Science Fund
Early Stage Biotech VC, 5AM Ventures, Grabs $250 Million
Life Science VC Firm 5AM Ventures Raising $240 Million for New Fund